RISA Labs, a company developing an artificial intelligence (AI) operating system for oncology, has closed an $11.1 million Series A funding round. The round was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon via his Ventureforgood investment entity.
The funding will accelerate deployment of RISA’s AI system across cancer clinics, health systems, specialty pharmacies, and infusion networks in the United States. The platform is designed to manage complex oncology workflows end-to-end, including patient access, benefits verification, and prior authorizations, transforming traditionally manual processes into streamlined, high-throughput operations.
RISA’s system integrates directly with electronic medical records (EMRs), payer and benefits systems, and other institutional tools. AI agents read, reason, and act across these systems, submitting authorizations, tracking status, and adapting automatically to changes in forms, rules, or interfaces. Institutions manage and configure workflows through RISA’s BOSS Console, which allows practices to tailor document routing, workflow rules, and practice-specific conventions while ensuring traceability and regulatory compliance.
The system is already operational at several large U.S. oncology practices, where it has significantly improved efficiency. Administrative staff time has been reduced by approximately 80%, denials have dropped by up to 40%, and first-pass approval rates have reached 97.8%. Patient authorizations are now processed within 24 hours, down from an average eight-day backlog, with plans to reduce processing times further. More than 20 full-time employees have been redeployed to higher-value tasks, boosting overall practice capacity and efficiency.
RISA Labs plans to expand its AI-driven workflows across the full continuum of cancer care in the coming year, including integration with specialty pharmacy operations. The company aims to address challenges posed by the growing patient population, increasingly complex treatment regimens, and a limited supply of oncologists, positioning its AI platform as a core operational tool for modern oncology.
Also Read